A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis

NCT00777868 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Onychomycosis

Interventions

DRUG: Low Strength IDP-108
DRUG: High Strength IDP-108
DRUG: High Strength IDP-108 under occlusion
DRUG: Vehicle

Sponsor

Dow Pharmaceutical Sciences